Altamira Therapeutics Ltd (CYTO)’s valuation ratios: A closer look

The closing price of Altamira Therapeutics Ltd (NASDAQ: CYTO) was $2.02 for the day, down -14.77% from the previous closing price of $2.37. In other words, the price has decreased by -$0.3500 from its previous closing price. On the day, 715809 shares were traded. CYTO stock price reached its highest trading level at $2.6730 during the session, while it also had its lowest trading level at $2.0063.

Ratios:

Our analysis of CYTO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.27 and its Current Ratio is at 0.32.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTO now has a Market Capitalization of 3.18M and an Enterprise Value of 7.04M. Its current Enterprise Value per Revenue stands at 58.54 whereas that against EBITDA is -0.31.

Stock Price History:

Over the past 52 weeks, CYTO has reached a high of $52.00, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is 2.3289, while the 200-Day Moving Average is calculated to be 6.5504.

Shares Statistics:

CYTO traded an average of 383.12K shares per day over the past three months and 204.99k shares per day over the past ten days. A total of 1.58M shares are outstanding, with a floating share count of 1.58M. Insiders hold about 0.00% of the company’s shares, while institutions hold 0.49% stake in the company. Shares short for CYTO as of Feb 15, 2024 were 60.44k with a Short Ratio of 0.16, compared to 39.76k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.84% and a Short% of Float of 3.84%.

Earnings Estimates

The firm’s stock currently is rated by 0 analysts. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.

Most Popular

[the_ad id="945"]